Abele Stefan Andreas sold $1.8M of PHVS

Abele Stefan Andreas (Chief Technical Ops Officer) sold 46,400 shares of Pharvaris N.V. (PHVS) at an average of $38.17 ($38.14–$39.24, $1.77M total) across 2 trades on 2026-09-15.

Original reporting
SEC EDGAR · Abele Stefan Andreas
Published Sep 17, 2026, 5:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 5:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as a negative cue by the market.

02

Market read

First‑report insider sale of a C‑level executive; modest materiality for a small‑cap biotech.

03

What to watch

No 10b5‑1 plan; the timing may be unrelated to company fundamentals.

Relevance 6/10Novelty 6/10Timing: filing disclosed on 2026-09-17

Background

SEC Form 4 filing discloses insider transactions; PHVS is a biotech listed on Nasdaq.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Chief Technical Ops Officer sold 46,400 shares for $1.77M, reducing his stake to 39,068 shares.

Expected impact

Modest downside pressure, likely 1‑2% dip over the next few days.

Evidence & confidence

C‑level insider sales are watched closely; the $1.8M sale is material for a small‑cap biotech and could trigger sell‑offs.

Market effects

May raise concerns for other biotech firms with recent insider sales.

Limited to US biotech investors; no broader regional effect.

Minimal global impact.

Counterpoint

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Pharvaris N.V.

    Biotech firm developing therapies for rare diseases.

  • Abele Stefan Andreas

    Chief Technical Ops Officer of Pharvaris.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.